A recent study published in the Nature demonstrates the potential of CHLOE, an AI decision support technology developed by Fairtility, to advance academic research in reproductive health. The study led by Professor Iris Har Vardi, an authority in the field of fertility and IVF, specifically focused on the impact of blastocyst morphometric parameters on implantation potential.
Professor Har Vardi, Director of Fertility and IVF Lab at Soroka University Medical Center and a Senior Lecturer at Ben Gurion University, serves as a scientific advisor to Fairtility. The study involved 608 transferred blastocysts, selected using morphokinetics and Gardner criteria. Using CHLOE’s transparent AI algorithms, the research team was able to retrospectively assess four key morphometric parameters: blastocyst size, inner cell mass (ICM) size, ICM-to-blastocyst size ratio, and ICM shape.
The study found a significant positive correlation between blastocyst size and implantation. For every 1 μm increase in blastocyst size, there was a relative increase in the odds of implantation by 2.1%. According to Professor Har Vardi, “CHLOE’s AI algorithms enabled us to measure various embryo components automatically with higher accuracy and speed than us, the embryologists. This research highlights the potential for enhanced blastocyst selection in the IVF process using AI technology, offering great promise for improving the effectiveness and personalization of reproductive healthcare.”
CHLOE’s capabilities extend beyond the clinical setting and into academic research. Its advanced, consistent, and automated assessments make it easier for researchers to objectively study various biomarkers, events, timing, and ratios that were previously difficult to measure, providing invaluable insights for treatment decisions.
Eran Eshed, Co-founder and CEO of Fairtility, noted: “Our mission is to advance and improve reproductive care through CHLOE. We can leverage AI technologies to elevate care in clinics and ensure researchers continue to advance our understanding to improve patient care in the long term.”
CHLOE offers various features such as automated embryo quality assessment (CHLOE EQ), oocyte assessment support (CHLOE OQ), and clinical and operational performance monitoring (CHLOE KPI). With its commitment to transparency, especially where AI intersects with human life, Fairtility aims to expand CHLOE’s applications across the entire reproductive care journey. This will range from assessing causes of infertility to optimizing embryo transfer, providing a comprehensive solution for clinicians and their patients.
